Shenqi Xingnao Granules ameliorates cognitive impairments and Alzheimer's disease-like pathologies in APP/PS1 mouse model

被引:0
|
作者
Cui-cui Yang [1 ]
Xiao-yu Jia [1 ]
Li Zhang [1 ]
Ya-li Li [1 ]
Zhan-jun Zhang [2 ,3 ]
Lin Li [1 ]
Lan Zhang [1 ]
机构
[1] Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing Institute for Brain Disorders, Beijing Engineering Research Center for Nerve System Drugs,Key Laboratory for Neurodegenerative Diseases of Ministry of Education
[2] State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University
[3] BABRI Centre, Beijing Normal University
关键词
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
1008 ;
摘要
Objective:Alzheimer’s disease(AD) is along with cognitive decline due to amyloid-β(Aβ) plaques,tau hyperphospho rylation,and neuron loss.Shenqi Xingnao Granules(SQXN),a traditional Chinese medicine,significantly ameliorated the cognitive function and daily living abilities of patients with AD.However,till date,no study has investigated the mechanism of action of SQXN on AD.The present study aimed to verify the effects of SQXN treatment on cognitive impairments and AD-like pathologies in APP/PS1 mice.Methods:Four-month-old APP/PS1 transgenic(Tg) mice were randomly divided into a model group and SQXN-treated(3.5,7,14 g/kg per day) groups.Learning-memory abilities were determined by Morris water maze and object recognition test.All mice were sacrificed and the brain samples were collected after 75 d.The soluble Aβ contents were detected by Elisa kit;The levels of expression of NeuN,APP,phosphorylated tau and related protein were measured by Western blotting;The inflammation factors were detected by the proinflammatory panel kit.Results:Four-month-old APP/PS1 mice were administered SQXN by oral gavage for 2.5 months.Using the Morris water maze tests and Novel object recognition,we found that SQXN restored behavioral deficits in the experimental group of Tg mice when compared with the controls.SQXN also inhibited neuronal loss(NeuN marker).SQXN treatment decreased soluble Aβ42 through inhibiting the expression of sAPPβ and BACE-1 without regulating full-length amyloid precursor protein(FL APP).Insulin degrading enzyme(IDE),the Aβ degrading enzyme,were increased by SQXN.In addition,SQXN reduced hyperphosphorylated tau protein levels and prevented excessive activation of p-GSK-3β in the brain of APP/PS1 mice.Compared with APP/PS1 transgenic negative mice,IFN-γ,IL-1β,IL-2,IL-4,IL-5,IL-6,IL-12 p70,KC/GRO and TNF-α were not obviously changed in the brain of 6.5-month-old APP/PS1 transgenic(Tg) mice.However,SQXN could inhibited the expression of IL-2.Conclusion:These results demonstrate that SQXN ameliorates the cognitive impairments in APP/PS1 mice.The possible mechanisms involve its inhibition of neuronal loss,soluble Aβ deposition,tau hyperphosphorylation and inflammation.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 50 条
  • [21] Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice
    Zhou, Fang
    Yan, Xu-Dong
    Wang, Chun
    He, Ye-Xin
    Li, Yi-Ying
    Zhang, Jun
    Wang, Zhao-Jun
    Cai, Hong-Yan
    Qi, Jin-Shun
    Wu, Mei-Na
    NEUROBIOLOGY OF AGING, 2020, 91 : 66 - 75
  • [22] DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease
    Cao, Yue
    Holscher, Christian
    Hu, Meng-Ming
    Wang, Ting
    Zhao, Fang
    Bai, Yu
    Zhang, Jun
    Wu, Mei-Na
    Qi, Jin-Shun
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 827 : 215 - 226
  • [23] Fecal microbiota transplantation alleviated Alzheimer’s disease-like pathogenesis in APP/PS1 transgenic mice
    Jing Sun
    Jingxuan Xu
    Yi Ling
    Fangyan Wang
    Tianyu Gong
    Changwei Yang
    Shiqing Ye
    Keyue Ye
    Dianhui Wei
    Ziqing Song
    Danna Chen
    Jiaming Liu
    Translational Psychiatry, 9
  • [24] Impact of Donepezil Supplementation on Alzheimer's Disease-like Pathology and Gut Microbiome in APP/PS1 Mice
    Li, Yuan
    Wu, Mengyao
    Kong, Mengmeng
    Sui, Shaomei
    Wang, Qi
    He, Yan
    Gu, Jinsong
    MICROORGANISMS, 2023, 11 (09)
  • [25] Fecal microbiota transplantation alleviated Alzheimer's disease-like pathogenesis in APP/PS1 transgenic mice
    Sun, Jing
    Xu, Jingxuan
    Ling, Yi
    Wang, Fangyan
    Gong, Tianyu
    Yang, Changwei
    Ye, Shiqing
    Ye, Keyue
    Wei, Dianhui
    Song, Ziqing
    Chen, Danna
    Liu, Jiaming
    TRANSLATIONAL PSYCHIATRY, 2019, 9 (1)
  • [26] Intramuscular delivery of p75NTR ectodomain by an AAV vector attenuates cognitive deficits and Alzheimer's disease-like pathologies in APP/PS1 transgenic mice
    Wang, Qing-Hua
    Wang, Ye-Ran
    Zhang, Tao
    Jiao, Shu-Sheng
    Liu, Yu-Hui
    Zeng, Fan
    Li, Jing
    Yao, Xiu-Qing
    Zhou, Hua-Dong
    Zhou, Xin-Fu
    Wang, Yan-Jiang
    JOURNAL OF NEUROCHEMISTRY, 2016, 138 (01) : 163 - 173
  • [27] Chronic administration of prebiotics and probiotics ameliorates pathophysiological hallmarks of Alzheimer's disease in a APP/PS1 transgenic mouse model
    Lana, Daniele
    Traini, Chiara
    Bulli, Irene
    Sarti, Giorgia
    Magni, Giada
    Attorre, Selene
    Giovannini, Maria Grazia
    Vannucchi, Maria Giuliana
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [28] TRANSCRIPTOMICS OF AGGRAVATED EPILEPTOGENESIS AND COGNITIVE DECLINE AFTER TBI IN APP/PS1 MOUSE MODEL OF ALZHEIMER'S DISEASE
    Pitkanen, Asla
    Miszczuk, Diana
    Debski, Kondrad
    Tanila, Heikki
    Lukasiuk, Katarzyna
    JOURNAL OF NEUROTRAUMA, 2015, 32 (12) : A77 - A77
  • [29] Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease
    Pugh, Perdita L.
    Richardson, Jill C.
    Bate, Simon T.
    Upton, Neil
    Sunter, David
    BEHAVIOURAL BRAIN RESEARCH, 2007, 178 (01) : 18 - 28
  • [30] The role of ADAM17 in cerebrovascular and cognitive function in the APP/PS1 mouse model of Alzheimer's disease
    Tian, Yanna
    Fopiano, Katie Anne
    Buncha, Vadym
    Lang, Liwei
    Suggs, Hayden A.
    Wang, Rongrong
    Rudic, R. Daniel
    Filosa, Jessica A.
    Bagi, Zsolt
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2023, 16